Exploring how certain short RNAs regulate gene expression in cells
Involvement of Noncanonical Short RNAs in gene repression through the RNA-induced-silencing complex
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-10867526
This study is looking at how tiny pieces of RNA can help control gene activity, especially in cancer patients, to find new ways to treat diseases linked to certain gene mutations.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-10867526 on ClinicalTrials.gov |
What this research studies
This research investigates the role of non-canonical short RNAs (ncsRNAs) in gene regulation, particularly focusing on their interaction with the RNA-induced silencing complex (RISC). The study aims to understand how specific subclasses of these short RNAs, such as tRNA-derived fragments, can either silence gene expression or be prevented from doing so by cellular mechanisms. By examining the pathways that control these short RNAs, the research seeks to uncover potential therapeutic targets, especially in the context of cancers associated with mutations in Isocitrate Dehydrogenase. Patients may benefit from insights gained into gene regulation that could lead to new treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers associated with Isocitrate Dehydrogenase mutations.
Not a fit: Patients with non-cancerous conditions or those without Isocitrate Dehydrogenase mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel therapeutic approaches for cancers by targeting gene regulation mechanisms.
How similar studies have performed: While the role of microRNAs in gene regulation is well-established, the specific focus on non-canonical short RNAs and their mechanisms is relatively novel and has not been extensively tested.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DUTTA, ANINDYA — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: DUTTA, ANINDYA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer cell line, Cancers